Background. The incidence and impact of adverse drug events (ADEs) leading to hospitalization and as a predominant risk factor for late graft loss has not been studied in transplantation. Methods. This was a longitudinal cohort study of adult kidney recipients transplanted between 2005 and 2010 and followed through 2013. There were 3 cohorts: no readmissions, readmissions not due to an adverse drug event, and adverse drug events contributing to readmissions. The rationale of the adverse drug events contribution to the readmission was categorized in terms of probability, preventability, and severity. Results. A total of 837 patients with 963 hospital readmissions were included; 47.9% had at least one hospital readmission and 65.0% of readmissions were deemed as having an ADE contribute. The predominant causes of readmissions related to ADEs included non-opportunistic infections (39.6%), opportunistic infections (10.5%), rejection (18.1%), and acute kidney injury (11.8%). Over time, readmissions due to under-immunosuppression (rejection) significantly decreased (−1.6% per year), while those due to over-immunosuppression (infection, cancer, or cytopenias) significantly increased (2.1% increase per year [difference 3.7%, P = .026]). Delayed graft function, rejection, creatinine, graft loss, and death were all significantly greater in those with an ADE that contributed to a readmission compared the other two cohorts (P < .05).
Due to major surgical and medical advancements during the past 40 years, kidney transplantation has become the gold standard treatment for end-stage renal disease, as it has demonstrated improved quantity and quality of life compared with remaining on dialysis. Currently, ≈400,000 Americans have end-stage renal disease and ≈93,000 await transplant. 1 Improving long-term graft survival will facilitate the reduction of the organ shortage disparity and it is likely that immunosuppression side effects, or adverse drug effects (ADEs), are a significant contributor to late graft loss, although this is not well-studied. 2 In the general population, medication side effects and ADEs are common and preventable, particularly those that lead to hospitalization. 3 However, there is limited data available to assess this within kidney transplantation. 1 In nontransplant patients, the overall rate of ADEs is 50.1 per 1,000 person-years, 13.8 being preventable and 38% categorized as serious or fatal. 4 More research on the true incidence rates of ADEs in kidney transplant recipients is needed, particularly those that are severe enough to lead to hospitalization. This may help facilitate a better understanding of mechanisms to optimize posttransplant immunosuppression monitoring and medication therapy management. This is particularly an issue as ADEs are associated with medication nonadherence, which is a major contributor to late acute rejection leading to graft loss. 5 There are high rates of hospital readmissions in kidney transplant recipients. Rehospitalization after kidney transplant is a strong Supported through grants from the National Institute of Diabetes and Digestive under Award numbers K23DK099440 and T35DK007431 and from the Agency for Healthcare Research and Quality under award number R18HS023754.
Presented at the 12th Annual Academic Surgical Congress in Las Vegas, NV, February 7-9, 2017. Readmissions also are very costly to the health care system; 28% of Medicare payments for kidney transplants recipients were due to 30-day readmission payments. 7 It is likely that a substantial proportion of hospital readmissions after kidney transplantation are related to immunosuppression side effects and ADEs, although etiologic studies in transplantation are limited. Thus, the aim of this study was to establish foundational information regarding the rate of ADEs contributing to hospitalization, the proportion of these that may be preventable, and the impact of ADE hospitalizations on posttransplant outcomes, including graft loss and death.
Materials and Methods

Study design and patients
This was a retrospective longitudinal cohort study. Institutional review board approval was obtained to conduct a detailed evaluation of medical records for all kidney recipients who received a transplant between July 2005 and December 2010 at our institution. We analyzed any hospital readmission to our hospital system from 2005 to 2013. We chose 2005 as a starting date because this is when contemporary immunosuppression started being used at our center (tacrolimus, mycophenolate, and antibody induction). We utilized the most contemporary cohort possible while allowing for long-term follow-up, which provides adequate power to assess impact on graft outcomes. All hospitalization records were reviewed in detail to determine the specific causes of the admission. All solitary kidney transplants occurring at our institution in the specified period were assessed for inclusion. Pediatrics, multiorgan transplants, those with a history of a nonrenal transplant and those lost to follow-up were excluded from this study.
ADE assessment
Definition of an ADE
The World Health Organization definition of an ADE is "an injury resulting from medical intervention related to a drug," which includes both preventable and unpreventable events. For this study, we utilized this definition to determine the incidence of ADEs contributing to hospitalization. 8 
Determination if an ADE contributed to the hospital readmission
Three individuals, a medical student, a PharmD, and a transplant surgeon all independently reviewed the readmission to determine the likelihood that an ADE contributed to the event. Discrepancies between reviewers were adjudicated, using similar methodology to Bates criteria. 9, 10 ADEs were categorized using the Naranjo criteria, thus assessing the relationship between each readmission event and the medications as "definite," "probable," "possible," and "doubtful." 9 In an attempt to dichotomize the results, the events categorized as "possible," "definite," or "probable" were counted as ADEs that caused or contributed to hospitalization.
ADE preventability
Using similar methodology to Bates et al, reviewers considered the timing of the symptoms and whether the symptoms could be contributed to the drug based on the strength of published data in order to assess for preventability. 9, 10 Each ADE was classified as "nonpreventable," "preventable," and "ameliorable." Preventable events where those due to errors that could have been entirely avoided and were very rare. Ameliorable events were those whose severity or duration could have been substantially reduced had different actions been taken. Ameliorable events also were those in which medication doses or regimens were adjusted in the hospital which led to improved outcomes. Nonpreventable were idiosyncratic reactions and other events not fitting into the 2 aforementioned categories.
ADE severity
The severity of each ADE was assessed using the US Department of Health and Human Services Common Terminology Criteria for Adverse Events version 4.0. The severity of each ADE was categorized by assessing the symptoms with which the patient presented as well as various laboratory findings during the hospitalization and linking them with the criteria set in the Common Terminology Criteria for Adverse Events version 4.0.
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Outcome measures
The primary outcome of interest was to determine the proportion of posttransplant hospitalizations that were partially or fully attributable to ADEs in adult kidney transplant recipients. The secondary outcome of interest was to assess for risk factors associated with hospitalizations for posttransplant ADEs. Additional outcomes captured for this study were to determine if hospitalization for an ADE increases the risk of acute rejection, graft loss, or death compared with those hospitalized for other issues or those without hospitalization. We also assessed the impact of time on the incidence of hospitalizations due to ADEs in terms of under and overimmunosuppression.
Statistical analysis
First, we utilized standard descriptive statistics to categorize the incidence and primary etiologies of readmissions, with percentages for categorical data and rates, medians and means for continuous data. To conduct the baseline comparisons between the 3 groups and discern risk factors, we utilized the χ 2 test for categorical data and the Kruskal-Wallis test for ordinal and continuous variables. The etiologies of readmissions over time were assessed by categorizing these into 3 groups: overimmunosuppression (infection, cancer, cytopenias), underimmunosuppression (rejection), and other. Rates over time were compared using linear regression to estimate the slopes of each etiology and comparing the slope difference for statistical significance through interaction terms. To assess for patient and graft survival, multivariable modeling using Cox regression was utilized. Prior to multivariable modeling, proportional hazards assumptions were assessed and determined to be valid using a time by ADE interaction term. Covariates of theoretical and clinical importance were included in the models to adjust for potential confounding. Adjusted estimated graft and patient survival rates were output and plotted in survival curves, stratified by hospitalization and etiology. Statistical analyses were completed using SAS version 9.4 (SAS Institute, Cary, NC) with adjusted survival curve plots created in SPSS version 23.0 (IBM Corp, Armonk, NY).
Results
Between 2005 and 2010, 837 adult patients receiving solitary kidney transplants and meeting inclusion criteria were analyzed for this study. During the 10-year follow-up period, the study cohort had 963 hospital readmissions, with 401 (47.9%) patients having at least one readmission to our institution and 626 (65.0%) of the hospital readmissions deemed to have an ADE causing or contributing to the event. Prevailing etiologies for hospital readmission were separated into 11 categories and compared across the readmission being due to an ADE ( Table 1 ). The predominant etiologies for ADE readmissions included infections, rejections, and acute kidney injuries not due to rejection or infection (calcineurin inhibitors toxicity, dehydration, and other nephrotoxins). Common causes of non-ADE related hospitalizations included cardiovascular events and surgical issues/complications. The likelihood of ADEs contributing to the hospitalization, the preventability assessment and ADE severity evaluation are displayed in Supplemental Tables 1 through 3 , respectively. The overwhelming majority of ADEs were assessed as probable, with most being assessed as ameliorable and graded as a severity level 3 (severe or medically significant but not life-threatening) or 4 (lifethreatening, urgent intervention needed).
Baseline characteristics were analyzed to determine risk factors for the development of an ADE that contributed to hospital readmission (Table 2 ). Significant risk factors included African American race, increased time on dialysis, increased time on waitlist and the kidney donor profile index. Receiving a living donor organ was significantly protective for ADEs.
Posttransplant outcomes were analyzed and compared across the cohorts (Table 3) . Delayed graft function and acute rejections were significantly more common in those with an ADE contributing to the admission. Posttransplant serum creatinine concentrations were greater in those with ADE readmissions. Adjusted graft and patient survival rates were lower in those with an ADE contributing to hospitalization compared with those without hospitalizations or those with non-ADE hospitalizations (Fig 1) . The prevailing etiologies of ADE readmissions over time are displayed in Fig 2. In 2005, ≈ 45% of ADE hospital readmissions were due to infection, cancer, or cytopenias and 25% were due to acute rejection. In contrast, in 2013, about 60% of ADE hospital readmissions were due to infection, cancer or cytopenias, while 10% were due to acute rejection. Based on regression estimates, ADE hospital readmissions due to overimmunosuppression increased by 2.1% per year, while ADE hospital readmissions due to underimmunosuppression decreased by 1.6% per year (estimated slope difference: 3.7% [95% confidence interval (CI), 1.0-6.4%]; P = .026).
Discussion
The results of this study demonstrate that ADEs may be a significant risk factor for hospital readmission and subsequent graft loss after kidney transplant. In addition, in this group of patients, these data demonstrate that ADEs associated with overimmunosuppression have significantly increased over time, while those associated with underimmunosuppression have decreased. Although these findings are to be expected, to our knowledge, this is the first study to comprehensively assess the incidence, etiologies, severity and impact of ADEs leading to hospital readmissions in kidney transplant recipients and provides true rates and risk estimates for these events. While the vast majority of ADEs leading to hospitalization were deemed not to be fully preventable by investigators, most are likely to be ameliorable with improved recognition of patient-specific risk factors, tailored immunosuppression management and, potentially, improved surveillance of patients' immune function status.
It is clear from this data that the majority of ADEs that led or contributed to hospitalization were related to infections, acute rejection episodes and acute kidney injury, often a result of calcineurin inhibitors toxicity. The increasing rate of infections, cytopenias and cancers as a predominant etiology for readmission is likely a direct result of the increased use of potent immunosuppression regimens (cytolytic induction therapy, tacrolimus, mycophenolate) in an aging recipient populations with more advanced comorbid conditions (diabetes, cardiovascular disease and obesity). 1 Although this also has clearly resulted in lower acute rejection episodes, it is evident that the impact of contemporary immunosuppression in an evolving kidney transplant population significantly increases the risk of ADEs related to overt overimmunosuppression. Because those with ADEs leading to hospital readmissions were at significantly higher risk of graft loss and death, future interventions need to focus on improving the individualization of immunosuppression regimens with the hopes of reducing the incidence and severity of ADEs and their downstream impact on outcomes. Transplantation hinges on the balance of over-and underimmunosuppression, and these events are intrinsically related to medications and thus adverse events. Defining them as ADEs and not simply as business as usual within transplantation will hopefully allow the transplant community to begin to address these in a more proactive manner.
Present strategies utilized in transplantation to identify and resolve ADEs before they lead to hospitalization tend to be nonspecific and reactionary in nature. Laboratory assessments focus on organ function, immunosuppressant medication concentrations and Table 3 Clinical outcomes compared between the three readmission cohorts.
Posttransplant outcomes
No readmission (n = 438, 52. IQR, interquartile range; SrCr, serum creatinine. Fig. 1 . Etiologies of admission overtime with estimated slope change for each category.
blood counts. 12 Unfortunately, these measures are not specific for true immune system functionality and tend to identify ADEs late in their course, thus resulting in hospitalization. Therapeutic drug monitoring using whole blood trough concentrations is universally used by transplant clinicians, yet the data demonstrating efficacy at predicting and preventing ADEs is mostly lacking. [13] [14] [15] Patients are asked to self-monitor home measurements of symptoms and vital signs, including blood pressures, temperatures, weights, and blood glucoses. Yet, in our experience within present clinical practice, this data is rarely reported to or reviewed by transplant clinicians in real-time. These factors lead a scenario where most transplant patients experiencing ADEs present to providers in clinic or the ER late in their course and thus need to be admitted to the hospital to manage the issue.
There are several potential mechanisms that may lead to a reduced incidence or severity of ADEs necessitating hospitalization. These include early identification through increased surveillance, immune functioning monitoring and improved recognition of medication errors and nonadherence. Another potential intervention is to improve the identification of patient-specific risk factors for over-or underimmunosuppression, with focused surveillance of these patients. The predominant causes of rehospitalization in this cohort were caused by overimmunosuppression. This potentially demonstrates that currently, monitoring immunosuppressant exposure through the use of drug levels does not truly assess the patient's functional immune status and largely ignores risks for overimmunosuppression, including advanced age, metabolic conditions, underlying immune deficiencies, neutropenia, and past exposure to immunosuppressants and chemotherapies. With the exception of immune function assays, there has been little progress in identifying a single data point that can alert clinicians to the functional state of the immune system. However, the use of immune function assays to predict infections has poor validation and significant heterogeneity, minimizing its utility in current practice. 16, 17 It may be that a multimodal monitoring system is necessary to alert clinicians to patients at risk of ADEs and readmissions. Electronic monitoring can be used to identify patients that have numerous risk factors for ADEs or have had past infections, which has been identified consistently as a risk factor for opportunistic infections. [18] [19] [20] [21] Another modality, mHealth monitoring, has the potential to alert clinicians to critical values or concerning trends in home monitoring, including blood sugars and blood pressure, allowing for early intervention before abnormalities culminate in an emergency room visit or hospitalization. Furthermore, prescription refill monitoring, in the form of Proportion of Days Covered reporting, or an mHealth enabled medication tray may also be useful in identifying *Models adjusted for age, gender, race, BMI, diabetes, cardiac history, years of dialysis, previous transplant, HLA mismatches, current & peak PRA, cold ischemic time, KDPI, pulsatile perfusion, induction therapy, maintenance immunosuppression and DGF Fig. 2 . Adjusted (*) survival curve estimates for graft loss (top) and death (bottom), compared between patients without readmissions versus admissions without ADEs versus admissions with ADEs. *Models were adjusted for age, sex, race, body mass index, diabetes, cardiac history, years of dialysis, previous transplant, human leukocyte antigen mismatches, current and peak panel reactive antibody, cold ischemic time, Kidney Donor Risk Index, pulsatile perfusion, induction therapy, maintenance immunosuppression and delayed graft function.
patients with poor adherence, and nonadherence has been shown to lead to readmissions and late rejections. [22] [23] [24] This study has several limitations warranting discussion. First, it was a retrospective, single institution analysis. Truly assessing ADEs, including definitive cause, preventability and severity is a difficult endeavor to undertake retrospectively, relying on data documented in the medical record. If documentation was poor or inaccurate, assessments were likely to be flawed. We attempted to mitigate this limitation using accepted methodology by Bates et al. 9, 10 Review and adjudication by several health care professionals should minimize this concern. Another limitation was that only readmissions to the study institution were captured and hospitalizations to outside facilities were not included. Based on recent data by Schold et al, 80% of hospitalizations during the first 3 months after transplant are to the transplant center, while only 52% are to the transplant center at 3 to 12 months posttransplant. 25 Thus, it is clear we did not capture all hospitalizations in this study and thus we did not set out to estimate the true rates of rehospitalization. This is a significant limitation to our study. It is currently unclear if readmissions to nontransplant hospitals have similar etiologies, and further research into the area is needed. Finally, it should be noted that this is a single-center study and these findings may not be generalizable to all kidney transplant recipients across the United States.
In conclusion, these results demonstrate that within this cohort of kidney transplant recipients, ADEs may be a significant risk factor for hospitalization and graft loss. Furthermore, within these patients, hospitalizations related to over immunosuppression (infections, cytopenias, and cancers) have significantly increased during the past 10 years.
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